Cavitation Technologies Files Q2 FY25 10-Q

TL;DR

Cavitation Technologies filed their 10-Q for Q2 FY25, check financials.

AI Summary

Cavitation Technologies, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the second quarter of their fiscal year 2025. The company's fiscal year ends on June 30th. The filing was made on February 14, 2025.

Why It Matters

This filing provides investors with an update on Cavitation Technologies' financial performance and operational status for the second quarter of their fiscal year 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly filing and does not appear to contain any immediately alarming information.

Key Players & Entities

• Cavitation Technologies, Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of reporting period
• 2025-02-14 (date) — Filing date
• 0630 (date) — Fiscal year end

FAQ

Key Financial Figures

• $5,465,000 — cently completed second fiscal quarter: $5,465,000 as of December 31, 2024 based on the cl
• $0.02 — 31, 2024 based on the closing price of $0.02 per share and 273,239,850 shares outsta
• $250,000 — Insurance Corporation ("FDIC") of up to $250,000. As of December 31, 2024, Company had
• $40,000 — ces, subject to certain limitations, of $40,000 to be applied against future sales of r
• $25,000 — smet also agreed to provide advances of $25,000 per month, subject to limitations. The

Filing Documents

• cavitation_i10q-123124.htm (10-Q) — 458KB
• cavitation_ex3101.htm (EX-31.1) — 7KB
• cavitation_ex3102.htm (EX-31.2) — 7KB
• cavitation_ex3201.htm (EX-32.1) — 3KB
• cavitation_ex3202.htm (EX-32.2) — 3KB
• logo.jpg (GRAPHIC) — 8KB
• 0001683168-25-001021.txt ( ) — 2730KB
• cvat-20241231.xsd (EX-101.SCH) — 20KB
• cvat-20241231_cal.xml (EX-101.CAL) — 30KB
• cvat-20241231_def.xml (EX-101.DEF) — 77KB
• cvat-20241231_lab.xml (EX-101.LAB) — 217KB
• cvat-20241231_pre.xml (EX-101.PRE) — 178KB
• cavitation_i10q-123124_htm.xml (XML) — 268KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23 PART II OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosure 24 Item 5. Other Information 24 Item 6. Exhibits 25

Signatures

Signatures 26 Certifications 2

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements. CAVITATION TECHNOLOGIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2024 June 30, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 681,000 $ 179,000 Inventory 11,000 – Prepaid expenses 9,000 16,000 Total current assets 701,000 195,000 Equity method investment 1,000 1,000 Operating lease right-of-use asset 6,000 42,000 Other assets 10,000 10,000 Total assets $ 718,000 $ 248,000 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses $ 164,000 $ 129,000 Accrued payroll and payroll taxes – related parties 434,000 414,000 Note payable 9,000 9,000 Operating lease liability, current portion 6,000 46,000 Total current liabilities 613,000 598,000 Note payable, non-current 128,000 130,000 Total liabilities 741,000 728,000 Commitments and contingencies – – Stockholders' deficit: Preferred stock, $ 0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and June 30, 2024 – – Common stock, $ 0.001 par value, 1,000,000,000 shares authorized, 284,289,740 shares issued and outstanding as of December 31, 2024 and June 30, 2024 284,000 284,000 Additional paid-in capital 26,188,000 26,083,000 Accumulated deficit ( 26,495,000 ) ( 26,847,000 ) Total stockholders' deficit ( 23,000 ) ( 480,000 ) Total liabilities and stockholders' deficit $ 718,000 $ 248,000 See accompanying notes to the condensed consolidated

financial statements

financial statements 3 CAVITATION TECHNOLOGIES, INC. CONDENSED CONSOLIDATED AS OF DECEMBER 31, 2024 AND 2023 For the Three Months Ended For the Six Months Ended December 31, December 31, 2024 2023 2024 2023 (unaudited) (unaudited) (unaudited) (unaudited) Revenue $ 76,000 $ 192,000 $ 76,000 $ 192,000 Cost of revenue ( 13,000 ) ( 34,000 ) ( 13,000 ) ( 34,000 ) Gross profit 63,000 158,000 63,000 158,000 General and administrative expenses 346,000 172,000 564,000 386,000 Research and development expenses 16,000 – 24,000 36,000 Total operating expenses 362,000 172,000 588,000 422,000 Loss from operations ( 299,000 ) ( 14,000 ) ( 525,000 ) ( 264,000 ) Other Income (expense) Gain on patent assignment 880,000 – 880,000 – Interest expense ( 2,000 ) ( 2,000 ) ( 3,000 ) ( 3,000 ) Net income (loss) $ 579,000 $ ( 16,000 ) $ 352,000 $ ( 267,000 ) Net income (loss) per share, Basic and diluted $ 0.00 $ ( 0.00 ) $ 0.00 $ ( 0.00 ) Weighted average shares outstanding, Basic and diluted 284,289,740 284,289,740 284,289,740 284,289,740 See accompanying notes to the condensed consolidated financial statements 4 CAVITATION TECHNOLOGIES, INC. CONDENSED CONSOLIDATED AS OF DECEMBER 31, 2024 AND 2023 Three Months Ended December 31, 2024 (unaudited) Common Stock Additional Paid-in Accumulated Shares Amount Capital Deficit Total Balance at September 30, 2024 284,289,740 $ 284,000 $ 26,083,000 $ ( 27,074,000 ) $ ( 707,000 ) Fair value of warrants granted for services – – 105,000 105,000 Net income – – – 579,000 579,000 Balance at December 31, 2024 284,289,740 $ 284,000 $ 26,188,000 $ ( 26,495,000 ) $ ( 23,000 ) Six Months Ended December 31, 2024 (unaudited) Common Stock Additional Paid-in Accumulated Shares Amount Capital Deficit Total Bal

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) Six months ended December 31, 2024 and 2023 Note 1 – Organization and Summary of Significant Accounting Policies Cavitation Technologies, Inc. ("the Company," "CTi," "we," "us," and "our") is a Nevada corporation originally incorporated in January 2007 under the name Bio Energy, Inc. The Company had originally developed, patented, and commercialized proprietary technology, which has subsequently been sold to Desmet Ballestra in the patent assignment and license back agreement disclosed below. Patent assignment and license back agreement On October 9, 2024, the Company has entered into an agreement with Desmet that monetized the Company by the assignment of certain of its U.S. and non-U.S. patents, technical information and related intellectual property (the "Assigned Patents") that for several years have been licensed to Desmet for its use on a global basis in vegetable oil, fats and oleo applications (see Note 2). Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and six months ended December 31, 2024 are not indicative of the results that may be expected for the fiscal year ending June 30, 2025. You should read these unaudited condensed consolidated financial statements in conjunction with the audited

View Full Filing

View this 10-Q filing on SEC EDGAR